Delivery Order SPE2DB20D1100-SPE2DB25FE6H8
- Not listed
- The Defense Logistics Agency awarded a $2,577.72 delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg, a pharmaceutical product for immunosuppression. The contract, awarded on July 31, 2025, with completion targeted for August 21, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive procurement. Performance will occur at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,035.60 on August 5, 2025, with an ultimate completion date of August 26, 2025. The contract involves the supply of Envarsus XR 1 mg tablets in a 30-tablet quantity under firm fixed-price terms. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a small-value transaction...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Envarsus XR 1 mg tablets (30-count packaging) under a firm fixed-price contract with a ceiling value of $1,165.05. The delivery order, classified as a non-set-aside competitive award, is scheduled for completion by September 9, 2025, with performance and delivery to occur at AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,151.68. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 16, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside contract, this award reflects AmerisourceBergen's capability to compete...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,288.86. This competitively awarded, firm fixed-price delivery order is set to be completed by September 8, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a single delivery order issued under a larger contract vehicle rather than a standalone...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,718.48 with firm fixed pricing and is scheduled for completion by September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain on July 28, 2025, for the supply of Envarsus XR 1 mg tablets (100-count packaging). This firm fixed price delivery order, valued at $2,148.10, is scheduled for completion by August 18, 2025, and represents a non-set-aside, competitively awarded contract. The delivery order is a child contract issued...
- The Defense Logistics Agency awarded a delivery order valued at $3,423.90 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Envarsus XR 4 mg tablets (100-count package). This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open solicitation. The contract is scheduled for completion by September 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $10,271.70 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (30-count supply) with a ceiling value of $1,553.40. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and has an ultimate completion date of August 18, 2025. The delivery order is being performed from AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is a child contract issued...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE6H8Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,577.72 for Envarsus XR 1 mg tablets (100-count) on September 12, 2025, with an ultimate completion date of October 3, 2025. The contract is structured as firm fixed price with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under the company's broader pharmaceutical supply relationship with the federal government. This award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply medications, vaccines, and medical supplies to military healthcare programs worldwide. Envarsus XR, an immunosuppressant medication, falls within the specialized pharmaceutical products covered under this prime vendor agreement, supporting the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 9/12/25 |